These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38331870)

  • 21. Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report.
    Loap P; Johnson N; Birsen R; Decroocq J; Kirova Y
    Strahlenther Onkol; 2024 Jul; ():. PubMed ID: 38955824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
    Weiss JM; Phillips TJ
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
    Kim J; Cho J; Lee MH; Yoon SE; Kim WS; Kim SJ
    Blood; 2024 May; ():. PubMed ID: 38696731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
    Carlo-Stella C
    Br J Haematol; 2024 Jul; 205(1):17-19. PubMed ID: 38813657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
    Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
    Mol Ther; 2024 May; ():. PubMed ID: 38822527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
    Howard AJ; Concepcion I; Wang AX; Hamadeh IS; Hultcrantz M; Mailankody S; Tan C; Korde N; Lesokhin AM; Hassoun H; Shah UA; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Chung DJ; Giralt S; Usmani SZ; Firestone RS
    Blood Adv; 2024 Jun; 8(12):3246-3253. PubMed ID: 38621239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
    Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma.
    Lownik J; Boiarsky J; Birhiray R; Merchant A; Mead M
    Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38661647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.
    Mariotti J; Zucchinetti C; Giordano L; De Philippis C; Mannina D; Sarina B; Taurino D; Carbon R; Santoro A; Bramanti S
    Cytotherapy; 2024 May; ():. PubMed ID: 38775776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.
    Pacis S; Bolzani A; Heuck A; Gossens K; Kruse M; Fritz B; Maywald U; Wilke T; Kunz C
    Oncol Ther; 2024 Jun; 12(2):293-309. PubMed ID: 38379108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.
    Bishop MR; Kay GE
    Semin Oncol; 2024 Feb; ():. PubMed ID: 38531760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy.
    Padmanabha N; Weinstock MJ; Xu S; Lepe M; Garrett LA; Kappes UP; Michaels PD
    J Hematop; 2024 Jun; ():. PubMed ID: 38878262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pivotal decade for bispecific antibodies?
    Surowka M; Klein C
    MAbs; 2024; 16(1):2321635. PubMed ID: 38465614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
    Crochet G; Iacoboni G; Couturier A; Bachy E; Iraola-Truchuelo J; Gastinne T; Cartron G; Fradon T; Lesne B; Kwon M; Gounot R; Martínez-Cibrian N; Castilla-Llorente C; Abrisqueta P; Guerreiro M; Sarkozy C; Aspa-Cilleruelo JM; Camus V; Guidez S; Chauchet A; Deconinck E; Bouabdallah K; Bosch F; Barba P; Morschhauser F; Houot R
    Blood; 2024 Apr; ():. PubMed ID: 38657242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibodies: Potential immunotherapies for HIV treatment.
    Fabozzi G; Pegu A; Koup RA; Petrovas C
    Methods; 2019 Feb; 154():118-124. PubMed ID: 30352254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
    Song YQ; Zhang HL; Huang HQ; Zhang QY; Jing HM; Wang C; Wu C; Li DH; Dai Y; Humphrey K; Zhu J
    Haematologica; 2024 Apr; 109(4):1269-1273. PubMed ID: 37855035
    [No Abstract]   [Full Text] [Related]  

  • 37. Mouse models of diffuse large B cell lymphoma.
    Tabatabai A; Arora A; Höfmann S; Jauch M; von Tresckow B; Hansen J; Flümann R; Jachimowicz RD; Klein S; Reinhardt HC; Knittel G
    Front Immunol; 2023; 14():1313371. PubMed ID: 38124747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.
    Visentin A; Frazzetto S; Trentin L; Chiarenza A
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives.
    Heitmann JS; Pfluegler M; Jung G; Salih HR
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535627
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.